The optimal duration of follow-up for patients who achieve sustained virologic responses (SVR) has become an important issue. Reports on long-term follow-up of SVR have indicated that 99% of patients maintained SVR. However, the limitations of a majority of studies include small patient numbers, short study periods, and lack of molecular analysis of hepatitis C virus (HCV) genome. The present study sought to evaluate the late relapse rate in long-term follow-up of patients who achieved SVR, with molecular analysis of HCV.
INTRODUCTION

I
T HAS BEEN estimated that 143 million individuals worldwide are infected with hepatitis C virus (HCV), which causes chronic hepatitis that can develop into potentially fatal cirrhosis and hepatocellular carcinoma (HCC). 1 Therefore, HCV infection is a major global health problem. Interferon (IFN) and ribavirin-based therapy has been used as a standard treatment for patients with chronic hepatitis C; however, it eradicates HCV in only 50% of patients with genotype 1. 2, 3 To improve the eradication rate of HCV, non-structural protein 3 (NS3) protease inhibitors have been developed and combined with IFN + ribavirinbased therapy. [4] [5] [6] [7] Interferon + NS3 protease inhibitor combination therapy can achieve sustained virologic response (SVR) in 80% of patients but has limitations, such as many adverse events. Better tolerated treatment options for patients ineligible for IFN-based therapy are needed. Interferon-free regimens were developed to overcome these shortcomings and are currently available in clinical practice. [8] [9] [10] [11] [12] Most IFN-free therapies lead to SVR in over 90% of patients. Thus, the number of patients who achieve SVR is increasing, and the optimal duration of follow-up for such patients has become a much more important issue. Reports on long-term follow-up of patients with chronic hepatitis C indicated that 99% of patients maintained SVR. 13 However, the limitations of a majority of studies investigating the recurrence of serum HCV RNA in patients who achieve SVR include small patient numbers and short follow-up periods. A major concern of previous studies is the lack of precise molecular analysis of the HCV genome, and few studies confirmed the same identical sequence in samples obtained at screening and those obtained after late relapse. [14] [15] [16] Therefore, it is possible that previous studies defined reinfection as late relapse. In this study, we evaluated the late relapse rate during long-term follow-up of chronic hepatitis C patients who achieved SVR, and undertook molecular analysis of HCV strains obtained at baseline and at the time of late relapse.
METHODS
A TOTAL OF 342patients with chronic hepatitis C who received IFN + ribavirin-based therapy at Nagoya University Hospital (Nagoya, Japan) were studied. Of the 342 patients, 224 who achieved SVR were enrolled. The patients' clinical characteristics are summarized in Table 1 . Patients with HIV and/or hepatitis B virus infection were excluded. The HCV genome was examined by direct sequencing. Identification of rs8099917, a single nucleotide polymorphism (SNP) in the IL28B gene, was carried out by real-time polymerase chain reaction (PCR). Patients received s.c. injections of standard IFN-α (6 mega units (MU)) daily for 2 weeks and then three times per week for at least 22 weeks with daily ribavirin (600 mg for <60 kg, 800 mg for 60-80 kg, 1000 mg for >80 kg body weight). Patients received s.c. injections of pegylated (Peg)-IFN-α2b (1.5 μg/kg) once weekly and ribavirin for weight dose with or without oral telaprevir or simeprevir daily for 6 months. Serum was stored at À80°C for virologic examination at pretreatment. Patients who were persistently negative for serum HCV RNA at 6 months after withdrawal of IFN treatment were considered to have a SVR. The other patients were considered to have non-SVR. This study was approved by the ethics committees of Nagoya University Hospital. Written informed consent was obtained from all patients, and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki.
Virologic analysis
The HCV RNA level was determined by PCR. Direct sequencing of the HCV core, NS3, and NS5A regions was carried out as reported previously. [17] [18] [19] [20] [21] In brief, RNA was extracted from 140 μL serum with a commercial kit (QIAamp Viral RNA Kit; Qiagen, Valencia, CA, USA) and dissolved in 50 μL diethyl pyrocarbonate-treated water. RNA (10 ng) was used for reverse transcription with oligo and random hexamer primers using a commercial kit (iScript cDNA Synthesis Kit; Bio-Rad, Hercules, CA, USA) for the HCV core region. Reverse transcription of NS3 and NS5A regions was undertaken using a commercial kit (SuperScript One-Step RT-PCR for long templates; Invitrogen, Tokyo, Japan) and a set of primers. The HCV core region was amplified by nested PCR. The NS3 and NS5A regions were amplified by single PCR. In brief, each 50-μL PCR reaction contained 100 nM of each primer, 1 ng template cDNA, and master mix reagent (AmpliTaq Gold 360 PCR Master Mix; Applied Biosystems, Foster City, CA, USA). Amplification conditions consisted of 10 min at 94°C, followed by 40 cycles of 94°C for 10 s, 55°C for 30 s, and 72°C for 30 s in a thermal cycler (GeneAmp PCR System 9700; Applied Biosystems). The second PCR was carried out in the same reaction buffer with the firstround PCR product as template, and second-round PCR primer sets. The PCR products were separated by electrophoresis on 2% agarose gels, stained with ethidium bromide, and visualized under ultraviolet light. The PCR products were then purified and sequenced with the second-round PCR primers using a dye terminator sequencing kit (BigDye Terminator v1.1 Cycle Sequencing Kit; Applied Biosystems) and an ABI 310 DNA Sequencer (Applied Biosystems). The neighbor-joining method 22 was used for phylogenetic analysis of the NS3 and NS5A regions for HCV genotype 1b and the core and NS5A regions for HCV genotype 2a. Bootstrap resampling and Late relapse and molecular analysis of HCV in SVR E79 Hepatology Research 2018; 48: E78-E86 reconstruction (1000 replicates) were carried out to confirm the reliability of the phylogenetic tree analysis.
Genomic analysis
Detection of rs8099917 was undertaken by real-time PCR. In brief, genomic DNA was extracted from 150 μL whole blood using a commercial kit (QIAamp DNA Blood mini Kit; Qiagen) and dissolved in 50 μL diethyl pyrocarbonate-treated water. DNA (10 ng) was used for PCR with primers and probes by a commercial kit (TaqMan SNP Genotyping Assays; Applied Biosystems). rs8099917 was amplified, and the results were analyzed by real-time PCR in a thermal cycler (7300 Real-Time PCR System; Applied Biosystems).
Statistical analysis
Data are expressed as means ± standard deviation. The follow-up rate was calculated by the Kaplan-Meier method. The statistical software used was SPSS (SPSS, Chicago, IL, USA).
RESULTS
F
IGURE 1 SHOWS THE long-term follow-up rate of patients who achieved SVR. The follow-up rate gradually decreased until 5 years and 20% of patients were lost to follow-up. However, after 5 years, only a few patients dropped out and most received consultation at the hospital. Figure 1 shows the measurement rate of HCV RNA. Although patients revisited for screening of HCC, HCV RNA was not evaluated in half of the patients. Two patients had detectable serum HCV RNA at 20 and 30 months, respectively, after SVR. Clinical characteristics and course of these two patients are summarized in Table 2 and Figure 2 , respectively. The results of the phylogenetic analyses of HCV core and NS5A regions of the late relapse patient with HCV genotype 2a are shown in Figure 3 . Randomly selected HCV genotype 2a strains from our report, 23 53 for the core region and 85 for the NS5A region, were aligned with samples collected from patients with late relapse. The samples at baseline and after late relapse were confirmed as the same strain. Figure 4 shows the results of phylogenetic analyses of HCV NS3 and NS5A regions of a late relapse patient with HCV genotype 1b. Randomly selected HCV genotype 1b strains from our previous report, 19, 21 34 for the NS3 region and 40 for the NS5A region, were aligned with three samples collected from different points (baseline at PegIFN + ribavirin therapy, baseline at PegIFN + ribavirin + simeprevir therapy, and late relapse after PegIFN + ribavirin + simeprevir therapy). The same strain was identified from all three samples with a few nucleotide changes. However, these nucleotide changes had no effect on the amino acid sequences. Therefore, there were no differences in the amino acid sequence of the NS3 region, including drug resistance-associated substitution (RAS) of simeprevir therapy (Fig. 5) .
DISCUSSION
P ATIENTS WHO WERE persistently negative for serum HCV RNA at 6 months after withdrawal of treatment were considered to have SVR. Relapse is often used to refer to detection of HCV RNA within 6 months of the end of treatment, and late relapse is used to refer to detection of Late relapse and molecular analysis of HCV in SVR E81 Hepatology Research 2018; 48: E78-E86 serum HCV RNA after determination of SVR. Although late relapse implies that reinfection occurs by the original strain, most studies did not analyze strains by sequencing methods. 13 Therefore, previous studies may have overestimated the rate of late relapse due to reinfection. 13, 24 Two patients in our study experienced a late relapse 20 and 30 months after determination of SVR. We undertook direct sequencing and phylogenetic analyses of two different regions at baseline and at the time of late relapse, and confirmed HCV recurred by the original strain. Patients may become reinfected by the initial source; however, our cases did not have high risk for reinfection, such as being a prisoner or an i.v. drug user.
One limitation of this study was that it was carried out in clinical practice. All patients were recommended to visit for follow-up every 6 or 12 months but doctors in charge made exceptions in some cases. At every visit, routine blood examination, including HCV RNA and α-fetoprotein, was carried out and ultrasound or computed tomography was used for screening for late relapse and HCC. Long-term follow-up studies have revealed the durability of SVR in chronic hepatitis C patients for 5 years. 13 However, the cumulative rates of HCC development in patients who achieved SVR on IFN-based therapy after 5 years are approximately 5%, and HCC occurred at the 10-year follow-up. [25] [26] [27] Thus, some doctors may discontinue evaluation of serum HCV after 5 years and only screen for HCC at every visit in daily practice. In this study, although the 8-year follow-up rate was 80%, only 40% of patients were monitored for incidence of HCC after SVR with measurement of serum HCV RNA. Thus, the durability of SVR and incidence of late relapse among patients who were lost to follow-up were unclear. It is difficult to determine whether this bias led to an underestimation or overestimation of late relapse. Our results indicated that the follow up of HCV RNA is necessary until at least 30 months after determination of SVR and monitoring of late relapse is effective but costly. The optimal term of monitor the serum HCV RNA is unknown and it is difficult to determine the duration for monitoring late relapse of HCV RNA. Patients with SVR should be examined for HCV RNA when their alanine aminotransferase levels are elevated again in spite of long-term follow-up. Further studies to investigate cost effectiveness and to determine the optimal period for monitoring of late relapse are needed, and these studies should be considered with a synchronizing analysis to screen for HCC after SVR.
Most relapsers treated with PegIFN + ribavirin + simeprevir therapy acquired RAS such as D168E/V after treatment failure. 28, 29 However, RAS in the NS3 region did not emerge in the patient who relapsed following PegIFN + ribavirin + simeprevir therapy. The mechanisms by which relapse and late relapse occur likely differ according to this emergence pattern of RAS. There is the possibility that this difference in the emergence patterns of RAS responsible for relapse and late relapse may have some effect on the different mechanisms involved in HCV recurrence. Several predictive markers for SVR such as the IFN sensitivity determining region (ISDR) in the NS5A region, core mutation, and SNPs of IL28B were reported. 19, 30, 31 Predictive factors for late relapse are useful to select high-risk groups to reduce the cost and efforts associated with long-term follow-up. Case 1 received half doses of PegIFN because of older age and low body weight (37 kg). This less powerful regimen would be associated with late relapse; however, a previous report indicated that the durability of SVR is not related to the treatment method. 32 The amino acid sequence of ISDR in case 1 was the same as in a previous case of late relapse.
14 However, this ISDR motif is the major type and frequently found in patients with chronic hepatitis C. Thus, the effect of ISDR on late relapse is unclear. Infection with HIV, use of immune modulators, and hypogammaglobulinemia were suggested as high-risk factors for late relapse. 13, 33 However, neither patient with late relapse had these risk factors. Assessment of the predictors for late relapse after IFN + ribavirin-based therapy was difficult due to the small number of patients.
Interferon-free therapy has become the standard of care for HCV patients and most studies have reported high SVR rates and good safety outcomes in real-world settings. [8] [9] [10] [11] [12] There is speculation that SVR by IFN-free therapy may be more durable than that by IFN-based therapy. Interferon-free therapy may directly eradicate HCV, whereas IFN-based therapy uses the immune system for HCV eradication. The latter is dependent on immune status, which could lead to HCV reactivation. The long-term durability of SVR by IFN-free therapy must be investigated in further studies because there is no evidence to support the notion that recurrence rates of IFN-free therapy are similar to those of IFN-based therapy.
In conclusion, although few patients may experience late relapse, SVR achieved by IFN-based therapy is durable for prolonged periods.
